Overview
Legal name
PRECIOUS MD LTD
Region
Unknown
Registered address
20-22 WENLOCK ROAD
LONDON
ENGLAND
N1 7GU
Insolvency history
No
Company
Active
LTD
Company profile
Precious MD Ltd
Precious MD
Precious MD is developing a companion diagnostic to identify the lung cancer patients who benefit from receiving EGFR inhibiting ...
CRN
11910010
Founded
2019
Age
7
Company events
Reference milestones and recent Companies House filing stream events.
7 events
10 Apr
2027
Confirmation statement due
Confirmation DueNext confirmation statement due date
31 Dec
2026
Accounts due
Accounts DueNext accounts due date
04 Apr
2026
Confirmation Statement With No Updates
Confirmation-statementCS01 | Transaction MzUxNDQyMDk3MmFkaXF6a2N4
Published 04 Apr 2026 12:54
27 Mar
2026
Confirmation statement filed
ConfirmationLast confirmation statement made up date
31 Mar
2025
Accounts filed
AccountsLast accounts made up date
12 Nov
2024
Accounts With Accounts Type Total Exemption Full
Accounts AnalysedAA | Transaction MzQ0MjgwMTMyMWFkaXF6a2N4
Published 12 Nov 2024 11:55
28 Mar
2019
Incorporated
InceptionCompany registered at Companies House
Public funding
4 awards
First funded
2021
Funded years
2021, 2023
Age at first award
2 years
Projects
2023
EU-Funded
Lead participant
Imaged-based Diagnostic to detect eligible lung cancer patients to receive Targeted therapy
1 Nov 2023 to 30 Jun 2024
Awarded
£63,520
Total cost £63,520
PreciousMD is female led and female dominated company found by Dr. Fatemeh Ameri in 2019 in London. At PreciousMD, we are developing a companion diagnostic to identify lung cancer pa-tients who can benefit from receiving epidermal-growth-factor receptor (EGFR) inhibi-ting drugs (i.e. targeted therapy). Worldwide, lung cancer is the most commonly diagnosed...
2023
Collaborative R&D
Lead participant
Smart cloud-based platform for lung cancer diagnostics validation
1 May 2023 to 31 Oct 2024
Awarded
£197,512
Total cost £282,160
More than one in three of us will get cancer in our lifetimes. Lung cancer is one of the most common and serious types of cancer. Around 46,500 people are diagnosed with the condition every year in the UK. Better prevention, earlier diagnosis and innovative new treatments mean we have a realistic opportunity to make major improvements in survival. Preciou...
2023
Grant for R&D
Lead participant
Smart web-based medical viewer for AI-based for EGFR mutation detection
1 Apr 2023 to 31 Mar 2024
Awarded
£50,000
Total cost £50,000
Dr. Fatemeh Ameri is the current CEO of Precious MD, a medical technology firm specialising in providing non-invasive, AI powered solutions for detection of gene mutations in lung cancer. She has backgrounds in Computer engineering, Electronic commerce and Marketing. She received her PhD in Business and Management from University of Manchester in 2015 and...
2021
Feasibility Studies
Lead participant
Decision support system for recommending EGFR-inhibiting drugs
1 Nov 2021 to 30 Apr 2023
Awarded
£187,782
Total cost £268,260
More than one in three of us will get cancer in our lifetimes. Lung cancer is one of the most common and serious types of cancer. Around 46,500 people are diagnosed with the condition every year in the UK. Better prevention, earlier diagnosis and innovative new treatments mean we have a realistic opportunity to make major improvements in survival. Preciou...
Product types
Collaborative R&D
EU-Funded
Feasibility Studies
Grant for R&D